D Hoelzer

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. doi request reprint High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients
    Albert Oriol
    Department of Hematology, ICO Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain
    Cancer 113:117-25. 2008
  2. pmc No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms
    Thomas Burmeister
    Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Retrovirology 4:11. 2007
  3. ncbi request reprint Recent approaches in acute lymphoblastic leukemia in adults
    D Hoelzer
    Medical Clinic III, University Hospital, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Crit Rev Oncol Hematol 36:49-58. 2000
  4. doi request reprint T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
    Dieter Hoelzer
    Onkologikum Frankfurt, D 60596 Frankfurt, Germany
    Clin Lymphoma Myeloma 9:S214-21. 2009
  5. ncbi request reprint Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia
    Dieter Hoelzer
    Medical Clinic III, Department of Hematology, University of Frankfurt, Germany
    Blood 99:4379-85. 2002
  6. doi request reprint Chemoimmunotherapy in acute lymphoblastic leukemia
    Dieter Hoelzer
    ONKOLOGIKUM, Frankfurt am Museumsufer, Frankfurt, Germany
    Blood Rev 26:25-32. 2012
  7. ncbi request reprint [Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]
    D Hoelzer
    Protokollkommission für die multizentrische Studiengruppe für die akute lymphatische Leukämie des Erwachsenen GMALL
    Internist (Berl) 43:1212-6, 1219-22, 1224-7. 2002
  8. doi request reprint Novel antibody-based therapies for acute lymphoblastic leukemia
    Dieter Hoelzer
    Goethe University Hospital, Frankfurt, Germany
    Hematology Am Soc Hematol Educ Program 2011:243-9. 2011
  9. ncbi request reprint Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes
    U Kalina
    Department of Hematology Oncology, Johann Wolfgang Goethe University Hospital, 60590, Frankfurt Main, Germany
    Exp Hematol 28:1158-63. 2000
  10. ncbi request reprint Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells
    U Kalina
    Department of Hematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Exp Hematol 29:602-8. 2001

Detail Information

Publications126 found, 100 shown here

  1. doi request reprint High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients
    Albert Oriol
    Department of Hematology, ICO Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain
    Cancer 113:117-25. 2008
    ..The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome and toxicity of HIV-positive patients with BL treated in a rituximab and intensive chemotherapy-based trial was evaluated...
  2. pmc No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms
    Thomas Burmeister
    Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Retrovirology 4:11. 2007
    ..The primer sequences were based on highly interspecies-conserved virus genome regions. We used this PCR to detect Deltaretroviruses in samples from adult patients with a variety of rare T-cell neoplasms in Germany...
  3. ncbi request reprint Recent approaches in acute lymphoblastic leukemia in adults
    D Hoelzer
    Medical Clinic III, University Hospital, J W Goethe University, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Crit Rev Oncol Hematol 36:49-58. 2000
    ..Subtype adjusted therapy, rational treatment decisions based on MRD and new, 'causative' treatment approaches are highlighted as the most promising perspectives for future improvement of treatment results in adult ALL...
  4. doi request reprint T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
    Dieter Hoelzer
    Onkologikum Frankfurt, D 60596 Frankfurt, Germany
    Clin Lymphoma Myeloma 9:S214-21. 2009
    ..Prognostic factors are published for T-ALL but not for T-LBL. MRD may guide further treatment strategies in T-ALL and probably also in T-LBL as indications for a SCT or for the evaluation of novel, particularly T-cell-specific, drugs...
  5. ncbi request reprint Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia
    Dieter Hoelzer
    Medical Clinic III, Department of Hematology, University of Frankfurt, Germany
    Blood 99:4379-85. 2002
    ..Mediastinal recurrence was the major obstacle and further improvement by intensification of chemotherapy, increased dose of mediastinal irradiation (36 Gy), and extended indications for stem cell transplantation seem to be required...
  6. doi request reprint Chemoimmunotherapy in acute lymphoblastic leukemia
    Dieter Hoelzer
    ONKOLOGIKUM, Frankfurt am Museumsufer, Frankfurt, Germany
    Blood Rev 26:25-32. 2012
    ..However, several details for an optimal treatment approach e.g. the required level of antigen expression, timing, schedule, dosage and stage of disease still need to be defined...
  7. ncbi request reprint [Acute lymphatic leukemia in the adult. Diagnosis, risk groups and therapy]
    D Hoelzer
    Protokollkommission für die multizentrische Studiengruppe für die akute lymphatische Leukämie des Erwachsenen GMALL
    Internist (Berl) 43:1212-6, 1219-22, 1224-7. 2002
  8. doi request reprint Novel antibody-based therapies for acute lymphoblastic leukemia
    Dieter Hoelzer
    Goethe University Hospital, Frankfurt, Germany
    Hematology Am Soc Hematol Educ Program 2011:243-9. 2011
    ..However, several details for an optimal treatment approach, such as the required level of antigen expression, timing, schedule, dosage, and stage of disease, still need to be defined...
  9. ncbi request reprint Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes
    U Kalina
    Department of Hematology Oncology, Johann Wolfgang Goethe University Hospital, 60590, Frankfurt Main, Germany
    Exp Hematol 28:1158-63. 2000
    ..This study therefore examined whether the impaired signaling in MDS and AML cells includes alterations of c-mpl itself or postsignaling events...
  10. ncbi request reprint Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells
    U Kalina
    Department of Hematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Exp Hematol 29:602-8. 2001
    ..To determine whether TGF-beta(1) interferes directly with TPO-induced signal transduction in hematopoietic cells, we compared the regulatory effects in the TPO-responsive cell lines Mo-7e and HEL...
  11. ncbi request reprint IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21
    U Kalina
    Department of Hematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    J Immunol 165:1307-13. 2000
    ..In contrast, proliferation of NK92 cells is not affected by MAPK p44erk-1 and p42erk-2...
  12. ncbi request reprint Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment
    U J Scheuring
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    Leukemia 17:1700-6. 2003
    ..Thus, these MRD parameters may guide timing and intensity of therapeutic modifications...
  13. ncbi request reprint Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation
    B Wassmann
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie, Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Bone Marrow Transplant 31:611-4. 2003
    ..This case illustrates the ability of imatinib to induce sustained hematologic and molecular remissions in some patients relapsing with advanced stage CML after alloSCT...
  14. ncbi request reprint A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chrom
    B Wassmann
    Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Ann Hematol 82:716-20. 2003
  15. ncbi request reprint Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W K Hofmann
    Department of Hematology Oncology, Johann Wolfgang Goethe University Hospital, University of Frankfurt Main, Theodor Stern Kai 7, Frankfurt Main, Germany
    Ann Hematol 83:498-503. 2004
    ..Thus, intensive chemotherapy with G-CSF priming is both well tolerated and highly effective for remission induction in these high-risk patients...
  16. doi request reprint Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia
    H Pfeifer
    Department of Hematology Oncology of the University Hospitals, Frankfurt, Germany
    Leukemia 27:1254-62. 2013
    ..Reappearance of BCR-ABL1 transcripts early after SCT or at higher levels identifies a small subset of patients who do not benefit sufficiently from imatinib, and in whom alternative approaches should be explored...
  17. ncbi request reprint Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome
    G Seipelt
    Medizinische Klinik III, Hämatologie Onkologie, Universitätsklinik Frankfurt, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Ann Hematol 80:170-3. 2001
    ....
  18. doi request reprint Human herpesvirus 6 in biopsies from patients with gastrointestinal symptoms after allogeneic stem cell transplantation
    S Mousset
    Medizinische Klinik II, J W Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Ann Hematol 91:737-42. 2012
    ..Thus, positive PCR results in GI tract samples do not necessarily reflect reactivation of HHV-6. Further studies are needed to define the significance of HHV-6 for GI tract symptoms after allo-SCT...
  19. ncbi request reprint Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)
    B Wassmann
    Department of Hematology, Medizinische Klinik III, Johann Wolfgang Goethe Universitat Frankfurt, Germany
    Leukemia 17:1919-24. 2003
    ..CNS prophylaxis is necessary and may enhance the antileukemic activity of imatinib and IFN-alpha...
  20. ncbi request reprint Genomic organization and regulation of the human interleukin-18 gene
    U Kalina
    Department of Hematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Scand J Immunol 52:525-30. 2000
    ..Cotransfection of STAT5 resulted in increased induction of the IL-18 promoter in the U937 and THP-1 cells...
  21. ncbi request reprint Imatinib for relapsed BCR/ABL positive leukemias
    O G Ottmann
    J W Goethe University, Medical Hospital III, Dept, Hematology Oncology, Theodor Stern Kai 7, 60596 Frankfurt, Germany
    Ann Hematol 81:S36-7. 2002
  22. ncbi request reprint Risk-adapted induction and consolidation therapy in adults with de novo AML aged </= 60 years: results of a prospective multicenter trial
    G Heil
    Department of Hematology, Hemostaseology and Oncology, Hannover Medical School, University of Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    Ann Hematol 83:336-44. 2004
    ..In conclusion, our risk-adapted strategy produced encouraging results in SR patients. Early response to therapy is a strong prognostic factor that predicts the probability of CR and long-term outcome...
  23. doi request reprint Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia
    H Pfeifer
    Department of Medicine, Hematology Oncology, Goethe University, Frankfurt, Germany
    Leukemia 26:1475-81. 2012
    ..Moreover, the prevalence of pre-existing, clinically relevant TKD may have been underestimated in tyrosine kinase inhibitor-naïve patients with Ph+ ALL...
  24. ncbi request reprint AC133 expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML
    F Fauth
    Department of Hematology, Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik III Hämatologie Onkologie, Knochenmarktransplantation, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Leuk Res 25:191-6. 2001
    ..6484, P=0.0121). In conclusion AC133 expression is closely related to CD34 expression in AML. In leukapheresis products AC133 provides an additional marker for selection of PBPC autografts in AC133- AML...
  25. ncbi request reprint TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34+ cells from healthy donors, but not from patients with AML after MDS
    S Koschmieder
    Division of Hematology, Department of Internal Medicine III, Johann Wolfgang Goethe University, Frankfurt, Germany
    Leukemia 15:942-9. 2001
    ..Thus, in MDS-derived AML, altered responses to TGF beta may be due to defects downstream of SMAD2 and may involve MAPK activation...
  26. ncbi request reprint Risk/MRD adapted GMALL trials in adult ALL
    N Gökbuget
    University Hospital, Medical Clinic III, 60590 Frankfurt, Germany
    Ann Hematol 83:S129-31. 2004
    ..In the future however an earlier identification of high risk patients (after 4 months) will be attempted...
  27. ncbi request reprint A new approach to evaluating intestinal acute graft-versus-host disease by transabdominal sonography and colour Doppler imaging
    S A Klein
    Medizinische Klinik III, Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Br J Haematol 115:929-34. 2001
    ..In conclusion, HRU is a useful tool for detecting acute bowel GvHD even before clinical symptoms. Moreover, HRU and CDI can be applied to define the severity of aGvHD and to identify patients with a poor prognosis...
  28. ncbi request reprint Induction of apoptosis by 2-chloro-2'deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone
    K U Chow
    Johann Wolfgang Goethe University Hospital, Department of Medicine III, Hematology Oncology, Frankfurt, Germany
    Leuk Lymphoma 36:559-67. 2000
    ..The synergistic lymphocytotoxic effect of 2-CdA combined with doxorubicin or mitoxantrone may be relevant for new treatment approaches...
  29. ncbi request reprint Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
    M J Rummel
    Department of Internal Medicine, Hematology Oncology, University Hospital, Theodor Stern Kai 7, 60590, Frankfurt Main, Germany
    Eur J Cancer 38:1739-46. 2002
    ..These results demonstrate that the combination of reduced-dose 2-CdA and mitoxantrone is a highly active regimen in the treatment of low-grade lymphomas, and in particular of MCL...
  30. ncbi request reprint Cytotoxic hepatosplenic gammadelta T-cell lymphoma following acute myeloid leukemia bearing two distinct gamma chains of the T-cell receptor. Biologic and clinical features
    E Weidmann
    Department of Medicine III, Hematology Oncology, University Hospital, Theodor Stern Kai 7, 60590 Frankfurt M, Germany
    Haematologica 85:1024-31. 2000
    ..Hepatosplenic gd T-cell lymphoma is a rare entity of peripheral T-cell lymphomas. We characterized in detail the first case of hepatosplenic gd -T-cell lymphoma following acute myeloid leukemia...
  31. ncbi request reprint Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome
    W K Hofmann
    Department of Hematology, University Hospital Benjamin Franklin, Berlin, Germany
    Leuk Res 30:1347-53. 2006
    ..These results indicate that hypermethylation of cell cycle control genes in MDS may occur late during the differentiation of myelodysplastic stem cells...
  32. ncbi request reprint Nonsecretory primary plasma cell leukemia with good response to thalidomide-based treatment
    P Bruck
    Department of Hematology and Oncology, University Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Int J Hematol 86:66-8. 2007
    ..We conclude that monotherapy with thalidomide might be an alternative maintenance strategy with limited response duration for patients with primary PCL in impaired general condition...
  33. doi request reprint Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008
    M Bruggemann
    Department of Hematology, University Hospital Schleswig Holstein, Campus Kiel, Kiel, Germany
    Leukemia 24:521-35. 2010
    ..The proposed MRD terminology may allow a refined and standardized assessment of response to treatment in adult and childhood ALL, and provides a sound basis for the comparison of MRD results between different treatment protocols...
  34. ncbi request reprint Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Ann Hematol 78:125-30. 1999
    ..We conclude that therapy with ATRA, IFNalpha, and G-CSF is effective in approximately 35% of low-risk MDS patients (in this study: six of 17) and may induce complete remission in individual cases...
  35. ncbi request reprint Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study
    A Bohme
    Department of Hematology Oncology, Johann Wolfgang Goethe University Frankfurt Germany
    Eur J Med Res 3:324-30. 1998
    ..In conclusion, PIP/TAZ as well as CEFP might be a sufficient initial therapy for febrile neutropenia, but further randomized trials with larger patient numbers are necessary...
  36. ncbi request reprint Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma
    E Weidmann
    Department of Medicine III, University Hospital, Frankfurt am Main, Germany
    Ann Oncol 13:1285-9. 2002
    ....
  37. ncbi request reprint Defective megakaryocytic development in myelodysplastic syndromes
    W K Hofmann
    Department of Haematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Leuk Lymphoma 38:13-9. 2000
    ....
  38. ncbi request reprint Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells
    B Moller
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik III, Frankfurt, Germany
    Inflamm Res 51:457-63. 2002
    ..High levels of IL-18 expression in RA joints are contrasted by reduced IL-18 expression in RA peripheral blood mononuclear cells (PBMC). Here, we investigated a putative IL-18 regulating role of corticosteroids...
  39. ncbi request reprint Rho family small GTPases control migration of hematopoietic progenitor cells into multicellular spheroids of bone marrow stroma cells
    G Bug
    Department of Internal Medicine III, University Hospital, J W Goethe University of Frankfurt, Germany
    J Leukoc Biol 72:837-45. 2002
    ..However, inhibition of the PI-3K pathway by LY294002 did not impair TF-1 cell migration in our three-dimensional model system...
  40. ncbi request reprint Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Ann Hematol 79:255-8. 2000
    ..5 pg/ml). In conclusion, treatment with amifostine as a single agent was of limited benefit in patients with RA. The serum TNF alpha levels were unchanged during treatment with amifostine in RA patients...
  41. ncbi request reprint [Epigenetic regulators as novel therapeutic targets in hematology/oncology]
    U Mahlknecht
    Klinikum der J W Goethe Universität Frankfurt am Main, Medizinische Klinik III, Abteilung für Hämatologie Onkologie, Frankfurt am Main
    Dtsch Med Wochenschr 128:2423-6. 2003
  42. ncbi request reprint Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse
    M J Rummel
    Med Klinik III, Johann Wolfgang Goethe Universitätsklinik, Frankfurt Main, Germany
    Ann Oncol 10:115-7. 1999
    ..The objective of this multicenter study was to evaluate the activity of cladribine in mantle-cell lymphomas as first-line therapy or in first relapse using an intermittent two-hour infusion of cladribine...
  43. ncbi request reprint High resolution physical mapping of human HDAC3, a potential tumor suppressor gene in the 5q31 region
    U Mahlknecht
    Laboratory of Medical Biochemistry, The Picower Institute for Medical Research, Manhasset NY, USA
    Cytogenet Cell Genet 86:237-9. 1999
    ..Since HDAC3 carries strong potential to be a tumor suppressor gene, we report herein its exact position between the CD14 and GRIA1 genes within the 5q31.1 subband...
  44. ncbi request reprint Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas
    M J Rummel
    Med Klinik III, Johann Wolfgang Goethe Universitätsklinik, Frankfurt Main, Germany
    Leuk Lymphoma 35:129-38. 1999
    ..To improve treatment results furthermore, cladribine should be combined with other agents active in low-grade lymphomas...
  45. ncbi request reprint Cloning and characterization of the murine histone deacetylase (HDAC3)
    U Mahlknecht
    Picower Institute for Medical Research, 350 Community Drive, Manhasset, New York, 11030, USA
    Biochem Biophys Res Commun 263:482-90. 1999
    ..We report herein the identification and characterization of HDAC3, a yeast RPD3 ortholog in the mouse. Studies on murine HDAC3 may yield important insights on the understanding of myeloproliferative disease in humans...
  46. ncbi request reprint Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha
    W K Hofmann
    Department of Haematology, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Eur J Haematol 62:336-40. 1999
    ..04). In conclusion, treatment with TFN alpha and ATRA did not result in improved megakaryocytopoiesis as assessed by in-vitro cultures. On the contrary, low-dose IFN alpha appears to suppress cell proliferation as well as MK development...
  47. ncbi request reprint Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia
    W K Hofmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60596 Frankfurt Main, Germany
    Ann Hematol 81:570-4. 2002
    ..The reduction of treatment costs by reducing the total G-CSF dose may be important in future treatment with this hematopoietic growth factor...
  48. ncbi request reprint Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34+ cell expansion and maturation
    S Koschmieder
    Department of Internal Medicine III, Johann Wolfgang Goethe University Hospital, Frankfurt Main, Germany
    Int J Hematol 73:71-7. 2001
    ..Neutralization experiments revealed differential contributions of Flt3 ligand and thrombopoietin to the support of total cell and CFC expansion by Sl/M2 and Sl/Sl stromal feeders...
  49. ncbi request reprint Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens
    S Hermann
    Department of Haematology and Oncology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Br J Haematol 113:446-54. 2001
    ....
  50. pmc Histone acetylation modifiers in the pathogenesis of malignant disease
    U Mahlknecht
    Department of Hematology Oncology, University of Frankfurt Medical Center, Germany
    Mol Med 6:623-44. 2000
    ....
  51. ncbi request reprint Assignment of the human histone deacetylase 6 gene (HDAC6) to X chromosome p11.23 by in situ hybridization
    U Mahlknecht
    University of Frankfurt, Department of Hematology Oncology, Theodor Stern Kai 7, DF 60590 Frankfurt am Main, Germany
    Cytogenet Cell Genet 93:135-6. 2001
  52. ncbi request reprint Treatment of aggressive, or progressing indolent peripheral T- and NK-cell neoplasias by combination of fludarabine, cyclophosphamide and doxorubicine
    E Weidmann
    Medizinische Klinik III, Universitatsklinik, Johann Wolfgang Goethe Universitat, Frankfurt M
    Onkologie 24:162-4. 2001
    ....
  53. ncbi request reprint Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes
    W K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
    Leuk Res 25:855-8. 2001
    ..However, our search for mutations in this gene did not identify somatic mutations in MDS. Our findings are consistent with the possible existence of an as-yet unknown tumor suppressor gene in this region that is altered in MDS...
  54. ncbi request reprint Chromosomal organization and localization of the human histone deacetylase 5 gene (HDAC5)
    U Mahlknecht
    Department of Hematology Oncology, University of Frankfurt Medical Center, Frankfurt, Germany
    Biochim Biophys Acta 1493:342-8. 2000
    ..84. Fluorescence in situ hybridization analysis localized the human HDAC5 gene to chromosome 17q21, a region which is characterized by frequent gains and losses of chromosomal material in several types of cancer...
  55. ncbi request reprint Assignment of the human histone deacetylase 4 gene (HDAC4) to chromosome 2q37.2 by in situ hybridization
    U Mahlknecht
    University of Frankfurt, Department of Hematology Oncology, Theodor Stern Kai 7, DF 60590 Frankfurt am Main, Germany
    Cytogenet Cell Genet 93:137-8. 2001
  56. ncbi request reprint Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
    W K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, UCLA School of Medicine, 8700 Beverly Boulevard, Suite B213, Los Angeles, CA 90048, USA
    Leuk Res 25:333-8. 2001
    ..The presence of a CHK2 mutation in MDS highlights the importance of alterations of cell cycle checkpoint genes in this disease...
  57. ncbi request reprint Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)
    B Wassmann
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie of the Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Leukemia 16:2358-65. 2002
    ..Disease status at time of transplantation is an important determinant of DFS and TRM...
  58. ncbi request reprint Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin
    U Arndt
    Medizinische Klinik III, Klinikum der Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Ann Hematol 84:159-66. 2005
    ..Retrospective analysis of the evaluable parameters (CHr, sTrfR, and ZnPP) revealed no additional benefit for predicting or monitoring IDE in this setting, although the one or other may be advantageous in other therapeutic situations...
  59. ncbi request reprint Inhibitory effect of azidothymidine, 2'-3'-dideoxyadenosine, and 2'-3'-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS
    A Ganser
    Department of Hematology, University of Frankfurt, FRG
    Exp Hematol 17:321-5. 1989
    ..The inhibition of progenitor cells from AIDS patients by the 2'-3'-dideoxynucleosides was comparable to normal progenitors, except for a higher sensitivity of AIDS-derived CFU-GEMM and BFU-E to AZT...
  60. ncbi request reprint Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data
    B Gleissner
    Department of Hematology, University Hospital Benjamin Franklin, Berlin, Germany
    Leukemia 15:1834-40. 2001
    ..Since false positive initial RT-nested-PCR data were frequent, either confirmatory second RT-PCR or FISH analysis is warranted to guarantee sensitive and reliable results of utmost clinical relevance...
  61. doi request reprint [Role of multicenter study groups for clinical research in hematology and oncology]
    N Gökbuget
    Klinikum der Goethe Universität, Zentrum der Inneren Medizin, Medizinische Klinik II, Theodor Stern Kai 7, 60590, Frankfurt
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 52:417-24. 2009
    ..Due to the considerable bureaucratic effort and increased costs, only few large multicenter trials could thereafter be initiated and a substantial disadvantage for independent academic research becomes clearly evident...
  62. ncbi request reprint Growth factors in the treatment of acute lymphoblastic leukemia
    O G Ottmann
    Department of Hematology and Oncology, Medizinische Klinik III des Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Leuk Res 22:1171-8. 1998
    ..As the remaining open questions are resolved, clinical benefits may be achieved consistently and with a favorable cost benefit ratio...
  63. ncbi request reprint Interleukin-10 expression: is there a neglected contribution of CD8+ T cells in rheumatoid arthritis joints?
    B Moller
    Klinikum der Johann Wolfgang Goethe Universitat, Medizinische Klinik III, Frankfurt, Germany
    Clin Exp Rheumatol 20:813-22. 2002
    ..To search for RA specific processes among T cell accumulation, T cell activation, or cytokine expression in CD4+ and CD8+ synovial fluid (SF) T cells...
  64. ncbi request reprint In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine
    K U Chow
    University Hospital, Department of Internal Medicine III, Hematology and Oncology, Frankfurt, Germany
    Haematologica 86:485-93. 2001
    ....
  65. ncbi request reprint Far-Western based protein-protein interaction screening of high-density protein filter arrays
    U Mahlknecht
    Department of Hematology Oncology, University of Frankfurt Medical Center, Theodor Stern Kai 7, D 60590, Frankfurt, Germany
    J Biotechnol 88:89-94. 2001
    ..Taken together, we describe an approach that allows the easy and reproducible identification of protein ligands on the basis of a whole-genome expression analysis...
  66. ncbi request reprint Protection against severe disease is conferred by DERAA-bearing HLA-DRB1 alleles among HLA-DQ3 and HLA-DQ5 positive rheumatoid arthritis patients
    C Seidl
    Department of Internal Medicine III, JW Goethe University, Frankfurt, Germany
    Hum Immunol 62:523-9. 2001
    ..5%) with predisposing DQ alleles alone (OR = 0.12, 95% CI: 0.02-0.72, p = 0.004). These results demonstrate a protective role of (70)DERAA(74)-positive DRB1 alleles against disease severity among RA patients...
  67. ncbi request reprint The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia
    T Karakas
    Medical Clinic III, Hematology Oncology, Ulm Donau, Germany
    Leukemia 16:846-54. 2002
    ..Thus, bcl-2 and wt1 mRNA expression are associated with response and long-term outcome in AMLs. The coexpression of these genes allows determination of prognostic groups with high predictive value for overall and disease-free survival...
  68. ncbi request reprint Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies
    Simone Boehrer
    Johann Wolfgang Goethe University Hospital, Department of Internal Medicine II, Hematology Oncology, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Curr Pharm Des 12:111-28. 2006
    ..While reviewing these molecular alterations this article moreover focuses on the impact of new therapeutic agents, which specifically exploit the knowledge of the molecular characteristics of malignant hematopoetic cells...
  69. ncbi request reprint Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia
    Gesine Bug
    Department of Internal Medicine II, University Hospital, JW Goethe University Frankfurt, Germany
    Cancer 104:2717-25. 2005
    ..Clinical responses to VPA were recently observed in patients with myelodysplastic syndrome (MDS). Herein, the authors have described results of a clinical trial with VPA plus ATRA in 26 patients with poor-risk AML...
  70. ncbi request reprint Clonal heterogeneity in growth kinetics of CD34+CD38- human cord blood cells in vitro is correlated with gene expression pattern and telomere length
    Kerol Bartolovic
    Department of Oncology and Hematology, University Hospital Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Stem Cells 23:946-57. 2005
    ..These data provide further evidence for a functional hierarchy in the human HSC compartment and suggest a link between telomere length and proliferation capacity of individual HSC clones...
  71. ncbi request reprint NUP214-ABL1 in adult T-ALL: the GMALL study group experience
    Thomas Burmeister
    Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30, 12200 Berlin, Germany
    Blood 108:3556-9. 2006
    ..Based on the results, we have established and tested a novel PCR method for simplified detection of the NUP214-ABL1 fusion gene...
  72. ncbi request reprint Expression of Daxx sensitizes Jurkat T-cells to the apoptosis-inducing effect of chemotherapeutic agents
    Simone Boehrer
    Department of Internal Medicine III, Hematology and Oncology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Pharmacol Res 51:367-74. 2005
    ..In order to elucidate the functional relevance of Daxx in the extrinsic signaling of malignant lymphocytes Jurkat T-cells were stably transfected with a Daxx-expressing vector or with the respective Daxx-negative control vector...
  73. ncbi request reprint Upon drug-induced apoptosis expression of prostate-apoptosis-response-gene-4 promotes cleavage of caspase-8, bid and mitochondrial release of cytochrome c
    Simone Boehrer
    Department of Medicine III, Johann Wolfgang Goethe University Hospital, Frankfurt, Germany
    Hematology 9:425-31. 2004
    ....
  74. ncbi request reprint Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells
    Gesine Bug
    Medizinische Klinik II Abteilung Hämatologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Cancer Res 65:2537-41. 2005
    ....
  75. ncbi request reprint Daxx overexpression in T-lymphoblastic Jurkat cells enhances caspase-dependent death receptor- and drug-induced apoptosis in distinct ways
    Simone Boehrer
    University Hospital, Department of Internal Medicine III, Hematology and Oncology, Theodor Stern Kai 7, 60590 Frankfurt Main, Germany
    Cell Signal 17:581-95. 2005
    ....
  76. ncbi request reprint Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma
    Mathias J Rummel
    Med Klinik II, Johann Wolfgang Goethe Universitätsklinik, Frankfurt Main, Germany
    J Clin Oncol 23:3383-9. 2005
    ....
  77. ncbi request reprint Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
    Marion G Ott
    Department of Hematology Oncology, University Hospital, German Cancer Research Center, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Nat Med 12:401-9. 2006
    ....
  78. ncbi request reprint Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells
    Daniel Nowak
    Department of Internal Medicine II, Hematology and Oncology, University Hospital, Theodor Stern Kai Germany
    Anticancer Drugs 18:981-95. 2007
    ..This study provides the first basis for establishing novel SrcK-I as weapons in the arsenal against lymphoma cells...
  79. ncbi request reprint Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome
    Claudia D Baldus
    Department of Hematology and Oncology, Charite, University Hospital Berlin, Campus Benjamin Franklin, Berlin, Germany
    J Clin Oncol 25:3739-45. 2007
    ..We hypothesized that like ERG, BAALC expression might be of prognostic significance in acute T-lymphoblastic leukemia (T-ALL) and that ERG and BAALC expression together would better identify the patient's risk profile...
  80. ncbi request reprint DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation
    Olaf Hopfer
    Department of Hematology, Oncology and Transfusion Medicine, Charite, Campus Benjamin Franklin, Berlin, Germany
    Exp Hematol 35:712-23. 2007
    ..Our data suggest that lineage-specific methylation-associated gene silencing of survivin, CHK2, and WT1 in MDS hematopoietic precursor cells may contribute to the MDS-specific phenotype..
  81. ncbi request reprint Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
    Gesine Bug
    Medizinische Klinik II, Abt Hämatologie Onkologie, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai 7, Frankfurt, Germany
    Haematologica 92:542-5. 2007
    ..Our data suggest a differential effect of VPA on the small population of AML progenitor cells and the bulk of aberrantly differentiated blasts in the majority of AML samples tested...
  82. ncbi request reprint Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Heike Pfeifer
    Center for Internal Medicine, Department of Hematology Oncology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Blood 110:727-34. 2007
    ..This provides a rationale for the frontline use of kinase inhibitors active against these BCR-ABL mutants...
  83. ncbi request reprint Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells
    Xiaomin Zheng
    Laboratory of Tumor Stem Cell Biology, Department of Hematology, J W Goethe University, Frankfurt, Germany
    Haematologica 92:323-31. 2007
    ..Arsenic induces high rates of CR and CMR followed by a long relapse-free survival (RFS). Here we compared the effects of ATRA and arsenic on PML/RARalpha-positive stem cell compartments...
  84. ncbi request reprint AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective
    Christian Hoffmann
    University Hospital of Schleswig Holstein, Campus Kiel, Kiel, Germany
    Leuk Lymphoma 47:1872-80. 2006
    ..Outcome may be improved compared to patients treated with CHOP-based regimens. In the era of HAART, more intensive chemotherapy regimens should be considered in patients with highly aggressive lymphomas...
  85. ncbi request reprint Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials
    Thorsten Raff
    Second Medical Department, University Schleswig Holstein, Campus Kiel, Germany
    Blood 109:910-5. 2007
    ..As a result of the study, as of spring 2006, salvage treatment in the ongoing GMALL trial is intended to be started at the time of recurrence of quantifiable MRD...
  86. ncbi request reprint Novel antibody-based therapy for acute lymphoblastic leukaemia
    Nicola Gökbuget
    J W Goethe University Hospital, Medical Clinic III, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Best Pract Res Clin Haematol 19:701-13. 2006
    ..Details of these regimens - required level of antigen expression, timing, schedule, dosage and stage of disease - remain to be defined...
  87. ncbi request reprint Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    N Engl J Med 354:2542-51. 2006
    ..Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50...
  88. ncbi request reprint Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Barbara Wassmann
    Department of Hematology and Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Blood 108:1469-77. 2006
    ..Both schedules of imatinib have acceptable toxicity and facilitate SCT in CR1 in the majority of patients, but concurrent administration of imatinib and chemotherapy has greater antileukemic efficacy...
  89. ncbi request reprint Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571
    Noriko Koyama
    Division of Hematology, Department of Internal Medicine II, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Cancer Res 12:2025-31. 2006
    ..In conclusion, functional PTP1B is involved in STI571-induced growth and cell cycle arrest, apoptosis, and differentiation, and attenuation of PTP1B function may contribute to resistance towards STI571...
  90. ncbi request reprint Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)
    Barbara Wassmann
    Departments of Hematology Oncology of University Hospitals Frankfurt, Hannover, Dresden, Munster, Ulm, Heidelberg, Munich, Germany
    Blood 106:458-63. 2005
    ..Continued detection of bcr-abl transcripts after 2 to 3 months on imatinib identifies patients who will ultimately experience relapse and in whom additional or alternative antileukemic treatment should be initiated...
  91. ncbi request reprint In malignant myeloid cells expression of Daxx downregulates expression of p53 and of the inhibitors of apoptosis proteins
    Simone Boehrer
    Department of Internal Medicine III, Hematology and Oncology, Johann Wolfgang Goethe University Hospital, 60590 Frankfurt am Main, Germany
    Hematol J 5:513-8. 2004
    ..Upon a proapoptotic stimulus such as serum withdrawal Daxx is unable to maintain its influence on expression levels of p53, Bax, IAPs and the procaspase-8, -10 and -7...
  92. ncbi request reprint Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms
    Patrick Bruck
    Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt a M, Germany
    Leuk Res 28:1153-7. 2004
    ..SNPs of PDGFR genes do not appear to play a role in patient's susceptibility to clinically severe edema formation during treatment with STI571...
  93. ncbi request reprint AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor
    Elena Puccetti
    Med Klinik III Abtl Hämatologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Cancer Res 62:7050-8. 2002
    ....
  94. ncbi request reprint Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Dieter Hoelzer
    Department of Hematology Oncology, University of Frankfurt, Frankfurt, Germany
    Semin Hematol 39:32-7. 2002
    ....
  95. ncbi request reprint Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
    Wolf K Hofmann
    Division of Hematology Oncology, Cedars Sinai Research Institute, Los Angeles, CA, USA
    Blood 100:3553-60. 2002
    ..Furthermore, this study provides evidence that in MDS, hematopoietic stem cells accumulate defects that prevent normal hematopoiesis...
  96. ncbi request reprint Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)
    Urban J Scheuring
    Medizinische Klinik III, Abteilung für Hämatologie und Onkologie of the Johann Wolfgang Goethe Universität, Frankfurt, Germany
    Blood 101:85-90. 2003
    ..The data show that Bcr-Abl levels in PB and BM after 2 weeks of imatinib treatment and in BM after 4 weeks have predictive relevance and may guide the application of additional therapies...
  97. ncbi request reprint Enhanced production of IL-18 in butyrate-treated intestinal epithelium by stimulation of the proximal promoter region
    Uwe Kalina
    Department of Hematology, University Hospital Frankfurt, Germany
    Eur J Immunol 32:2635-43. 2002
    ..In conclusion, SCFA up-regulate IL-18 protein expression in IEC, suggesting a potential regulatory contribution of these luminal constituents to T cell mediated inflammatory and neoplastic intestinal conditions...
  98. ncbi request reprint Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives
    Mathias J Rummel
    Department of Hämatologie Onkologie, Medizinische Universitatsklinik, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Semin Oncol 29:27-32. 2002
    ..Optimal treatment regimens with bendamustine in the treatment of low-grade NHL are yet to be defined, but results obtained to date indicate that further studies are warranted...
  99. ncbi request reprint In vitro studies with bendamustine: enhanced activity in combination with rituximab
    Mathias J Rummel
    Department of Internal Medicine III, Hematology and Oncology, University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Semin Oncol 29:12-4. 2002
    ..The actions of the combination of bendamustine and rituximab on ex vivo B-cell chronic lymphocytic leukemia cells and the DOHH-2 cell line, derived from CD20-positive lymphoma cells, are discussed in this article...
  100. ncbi request reprint Chromosomal organization and localization of the human histone deacetylase 9 gene (HDAC9)
    Ulrich Mahlknecht
    University of Frankfurt Medical Center, Department of Hematology Oncology, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Biochem Biophys Res Commun 293:182-91. 2002
    ..3 kDa and an isoelectric point of 6.41. Fluorescence in situ hybridization analysis localized the human HDAC9 gene to chromosome 7p21, a region which has been associated particularly with the pathogenesis of gynecological tumors...
  101. ncbi request reprint Differential effects of histone deacetylase inhibitors on interleukin-18 gene expression in myeloid cells
    Noriko Koyama
    Department of Hematology, Johann Wolfgang Goethe University, Frankfurt, 60590, Germany
    Biochem Biophys Res Commun 292:937-43. 2002
    ..While sodium butyrate or TSA stimulated the 108-bp IL-18 minimal promoter, valproate failed to activate it, indicating that valproate may use a distinct mechanism from sodium butyrate and TSA to activate IL-18 gene expression...